SUPPLEMENT

Q3 2023 — Financial disclosures

Q3 2023PDF · 10 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2023
Table of Contents
Table 1: GAAP P&L.....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter..................2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q23 and Sept YTD 23........3
Table 2b: GAAP to Non-GAAP Reconciliation 3Q22 and Sept YTD 22........4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 3Q23........................................................6
Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 23.............................................7
Table 3c: Sales – Pharmaceutical Geographic Split.....................................8
Table 4: Other (Income) Expense ..............................................................9

-- 1 of 10 --

Sales 	15,962	$ 	14,959	$ 	7% 	45,485	$ 	45,453	$ 	–
Costs, Expenses and Other
Cost of sales 	4,264 	3,934 	8% 	12,214 	13,530 	-10%
Selling, general and administrative 	2,519 	2,520 	– 	7,700 	7,355 	5%
Research and development 	3,307 	4,399 	-25% 	20,904 	9,773 	*
Restructuring costs 	126 	94 	34% 	344 	288 	19%
Other (income) expense, net 	126 	429 	-71% 	388 	1,576 	-75%
Income Before Taxes 	5,620 	3,583 	57% 	3,935 	12,931 	-70%
Taxes on Income 	870 	330 	2,332 	1,423
Net Income 	4,750 	3,253 	46% 	1,603 	11,508 	-86%
Less: Net Income Attributable to Noncontrolling Interests 	5 	5 	12 	6
Net Income Attributable to Merck & Co., Inc. 	4,745	$ 	3,248	$ 	46% 	1,591	$ 	11,502	$ 	-86%
Earnings per Common Share Assuming Dilution 	1.86	$ 	1.28	$ 	45% 	0.62	$ 	4.53	$ 	-86%
Average Shares Outstanding Assuming Dilution 	2,546 	2,542 	2,549 	2,540
Tax Rate 	15.5% 	9.2% 	59.3% 	11.0%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
3Q23 	3Q22 Sep YTD
2023
Sep YTD
2022
1

-- 2 of 10 --

Sales 	14,487	$ 	15,035	$ 	15,962	$ 	45,485	$ 	15,901	$ 	14,593	$ 	14,959	$ 	45,453	$ 	13,830	$ 	59,283	$ 	7% 	–
Costs, Expenses and Other
Cost of sales 	3,926 	4,024 	4,264 	12,214 	5,380 	4,216 	3,934 	13,530 	3,881 	17,411 	8% 	-10%
Selling, general and administrative 	2,479 	2,702 	2,519 	7,700 	2,323 	2,512 	2,520 	7,355 	2,687 	10,042 	– 	5%
Research and development 	4,276 	13,321 	3,307 	20,904 	2,576 	2,798 	4,399 	9,773 	3,775 	13,548 	-25% 	*
Restructuring costs 	67 	151 	126 	344 	53 	142 	94 	288 	49 	337 	34% 	19%
Other (income) expense, net 	89 	172 	126 	388 	708 	438 	429 	1,576 	(75) 	1,501 	-71% 	-75%
Income (Loss) Before Taxes 	3,650 	(5,335) 	5,620 	3,935 	4,861 	4,487 	3,583 	12,931 	3,513 	16,444 	57% 	-70%
Income Tax Provision 	825 	637 	870 	2,332 	554 	538 	330 	1,423 	495 	1,918
Net Income (Loss) 	2,825 	(5,972) 	4,750 	1,603 	4,307 	3,949 	3,253 	11,508 	3,018 	14,526 	46% 	-86%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	3 	5 	12 	(3) 	5 	5 	6 	1 	7
Net Income (Loss) Attributable to Merck & Co., Inc. 	2,821	$ 	(5,975)	$ 	4,745	$ 	1,591	$ 	4,310	$ 	3,944	$ 	3,248	$ 	11,502	$ 	3,017	$ 	14,519	$ 	46% 	-86%
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.11	$ 	(2.35)	$ 	1.86	$ 	0.62	$ 	1.70	$ 	1.55	$ 	1.28	$ 	4.53	$ 	1.18	$ 	5.71	$ 	45% 	-86%
Average Shares Outstanding Assuming Dilution (1) 	2,551 	2,539 	2,546 	2,549 	2,537 	2,540 	2,542 	2,540 	2,548 	2,542
Tax Rate 	22.6% 	-11.9% 	15.5% 	59.3% 	11.4% 	12.0% 	9.2% 	11.0% 	14.1% 	11.7%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
2022
Sep YTD
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
% Change
3Q 	Sep YTD
(1) Because the company recorded a net loss in the second quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have
been anti-dilutive.
2023
2Q 	3Q 	Sep YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2

-- 3 of 10 --

Third Quarter
Cost of sales 	4,264	$ 	552 	33 	585 	3,679	$
Selling, general and administrative 	2,519 	17 	40 	57 	2,462
Research and development 	3,307 	10 	10 	3,297
Restructuring costs 	126 	126 	126 	–
Other (income) expense, net 	126 	(24) 	17 	(7) 	133
Income Before Taxes 	5,620 	(555) 	(199) 	(17) 	(771) 	6,391
Income Tax Provision (Benefit) 	870 	(53) (4) 	(32) (4) 	(4) (4) 	(89) 	959
Net Income 	4,750 	(502) 	(167) 	(13) 	(682) 	5,432
Net Income Attributable to Merck & Co., Inc. 	4,745 	(502) 	(167) 	(13) 	(682) 	5,427
Earnings per Common Share Assuming Dilution 	1.86	$ 	(0.20) 	(0.07) 	– 	(0.27) 	2.13	$
Tax Rate 	15.5% 	15.0%
Sep YTD
Cost of sales 	12,214	$ 	1,564 	94 	1,658 	10,556	$
Selling, general and administrative 	7,700 	62 	93 	155 	7,545
Research and development 	20,904 	29 	1 	30 	20,874
Restructuring costs 	344 	344 	344 	–
Other (income) expense, net 	388 	(12) 	(218) 	573 (3) 	343 	45
Income Before Taxes 	3,935 	(1,643) 	(532) 	218 	(573) 	(2,530) 	6,465
Income Tax Provision (Benefit) 	2,332 	(249) (4) 	(88) (4) 	47 (4) 	(60) (4) 	(350) 	2,682
Net Income 	1,603 	(1,394) 	(444) 	171 	(513) 	(2,180) 	3,783
Net Income Attributable to Merck & Co., Inc. 	1,591 	(1,394) 	(444) 	171 	(513) 	(2,180) 	3,771
Earnings per Common Share Assuming Dilution 	0.62	$ 	(0.55) 	(0.18) 	0.07 	(0.20) 	(0.86) 	1.48	$
Tax Rate 	59.3% 	41.5%
Only the line items that are affected by non-GAAP adjustments are shown.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2a
Certain Other Items
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and
forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP
information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income,
partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the nine-month period includes a $37
million loss on the sale of a business.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
3

-- 4 of 10 --

Third Quarter
Cost of sales 	3,934	$ 	446 	54 	500 	3,434	$
Selling, general and administrative 	2,520 	22 	26 	48 	2,472
Research and development 	4,399 	902 	1 	903 	3,496
Restructuring costs 	94 	94 	94 	–
Other (income) expense, net 	429 	(26) 	350 	324 	105
Income Before Taxes 	3,583 	(1,344) 	(175) 	(350) 	(1,869) 	5,452
Income Tax Provision (Benefit) 	330 	(302) (3) 	(35) (3) 	(77) (3) 	(414) 	744
Net Income 	3,253 	(1,042) 	(140) 	(273) 	(1,455) 	4,708
Net Income Attributable to Merck & Co., Inc. 	3,248 	(1,042) 	(140) 	(273) 	(1,455) 	4,703
Earnings per Common Share Assuming Dilution 	1.28	$ 	(0.40) 	(0.06) 	(0.11) 	(0.57) 	1.85	$
Tax Rate 	9.2% 	13.6%
Sep YTD
Cost of sales 	13,530	$ 	1,577 	167 	1,744 	11,786	$
Selling, general and administrative 	7,355 	137 	74 	211 	7,144
Research and development 	9,773 	936 	30 	966 	8,807
Restructuring costs 	288 	288 	288 	–
Other (income) expense, net 	1,576 	(138) 	1,268 	1,130 	446
Income Before Taxes 	12,931 	(2,512) 	(559) 	(1,268) 	(4,339) 	17,270
Income Tax Provision (Benefit) 	1,423 	(587) (3) 	(97) (3) 	(281) (3) 	(965) 	2,388
Net Income 	11,508 	(1,925) 	(462) 	(987) 	(3,374) 	14,882
Net Income Attributable to Merck & Co., Inc. 	11,502 	(1,925) 	(462) 	(987) 	(3,374) 	14,876
Earnings per Common Share Assuming Dilution 	4.53	$ 	(0.76) 	(0.18) 	(0.39) 	(1.33) 	5.86	$
Tax Rate 	11.0% 	13.8%
Only the line items that are affected by non-GAAP adjustments are shown.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management
uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is
derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with
GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain
other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the three and nine month periods primarily reflect $887 million of intangible asset impairment
charges largely related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net,
for the three and nine month periods primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-
Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal
MERCK & CO., INC.
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
4

-- 5 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2023 	2022 	3Q 	Sep YTD
1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	Nom % Ex-Exch % 	Nom % Ex-Exch %
TOTAL SALES (1) 	$14,487 	$15,035 	$15,962 	$45,485 	$15,901 	$14,593 	$14,959 	$45,453 	$13,830 	$59,283 	7 	9 	- 	3
PHARMACEUTICAL 	12,721 	13,457 	14,263 	40,442 	14,107 	12,756 	12,963 	39,826 	12,180 	52,005 	10 	11 	2 	4
Oncology
Keytruda 	5,795 	6,271 	6,338 	18,403 	4,809 	5,252 	5,426 	15,487 	5,450 	20,937 	17 	17 	19 	21
Alliance Revenue – Lynparza (2) 	275 	310 	299 	884 	266 	275 	284 	825 	292 	1,116 	5 	6 	7 	10
Alliance Revenue – Lenvima (2) 	232 	242 	260 	734 	227 	231 	202 	660 	216 	876 	29 	30 	11 	13
Welireg 	42 	50 	54 	146 	18 	27 	38 	83 	40 	123 	43 	43 	77 	77
Alliance Revenue – Reblozyl (3) 	43 	47 	52 	142 	52 	33 	39 	124 	41 	166 	35 	35 	14 	14
Vaccines (4)
Gardasil / Gardasil 9 	1,972 	2,458 	2,585 	7,015 	1,460 	1,674 	2,294 	5,428 	1,470 	6,897 	13 	16 	29 	34
ProQuad / M-M-R II / Varivax 	528 	582 	713 	1,823 	470 	578 	668 	1,716 	526 	2,241 	7 	6 	6 	6
RotaTeq 	297 	131 	156 	584 	216 	173 	256 	644 	139 	783 	-39 	-39 	-9 	-8
Vaxneuvance 	106 	168 	214 	488 	5 	12 	16 	32 	138 	170 	* 	* 	* 	*
Pneumovax 23 	96 	92 	140 	327 	173 	153 	131 	457 	145 	602 	6 	4 	-28 	-27
Vaqta 	40 	42 	69 	151 	36 	35 	64 	134 	39 	173 	8 	9 	12 	13
Hospital Acute Care
Bridion 	487 	502 	424 	1,413 	395 	426 	423 	1,244 	441 	1,685 	- 	- 	14 	15
Prevymis 	129 	143 	157 	430 	94 	103 	114 	310 	118 	428 	38 	38 	39 	41
Dificid 	65 	76 	74 	215 	52 	66 	77 	196 	67 	263 	-4 	-4 	10 	10
Primaxin 	80 	53 	41 	174 	58 	64 	63 	185 	54 	239 	-35 	-31 	-6 	-
Noxafil 	60 	55 	51 	167 	57 	60 	62 	180 	58 	238 	-18 	-12 	-7 	-1
Zerbaxa 	50 	54 	53 	157 	30 	46 	43 	120 	49 	169 	23 	22 	31 	33
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	99 	68 	92 	259 	72 	98 	88 	258 	82 	341 	5 	5 	- 	-
Adempas (6) 	59 	65 	65 	189 	61 	63 	57 	181 	57 	238 	15 	11 	5 	7
Virology
Lagevrio 	392 	203 	640 	1,236 	3,247 	1,177 	436 	4,859 	825 	5,684 	47 	51 	-75 	-73
Isentress / Isentress HD 	123 	136 	119 	377 	158 	147 	161 	466 	167 	633 	-27 	-27 	-19 	-17
Neuroscience
Belsomra 	56 	63 	58 	176 	69 	69 	62 	199 	59 	258 	-6 	-4 	-11 	-6
Immunology
Simponi 	180 	180 	179 	539 	186 	181 	173 	540 	166 	706 	3 	-2 	- 	-
Remicade 	51 	48 	45 	144 	61 	53 	49 	163 	44 	207 	-8 	-10 	-12 	-10
Diabetes (7)
Januvia 	551 	511 	581 	1,642 	779 	756 	717 	2,252 	561 	2,813 	-19 	-17 	-27 	-24
Janumet 	329 	354 	255 	937 	454 	476 	417 	1,347 	353 	1,700 	-39 	-38 	-30 	-28
Other Pharmaceutical (8) 	584 	553 	549 	1,690 	602 	528 	603 	1,736 	583 	2,319 	-9 	-7 	-3 	-
ANIMAL HEALTH 	1,491 	1,456 	1,400 	4,347 	1,482 	1,467 	1,371 	4,320 	1,230 	5,550 	2 	2 	1 	3
Livestock 	849 	807 	874 	2,530 	832 	826 	829 	2,486 	814 	3,300 	5 	7 	2 	6
Companion Animal 	642 	649 	526 	1,817 	650 	641 	542 	1,834 	416 	2,250 	-3 	-4 	-1 	-
Other Revenues (9) 	275 	122 	299 	696 	312 	370 	625 	1,307 	420 	1,728 	-52 	-18 	-47 	-19
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $950 million, $951 million and $924 million in the first, second and third quarter of 2023, respectively, and $1,305 million, $1,300 million and $1,231 million in the first,
second and third quarter of 2022, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively, and $114
million, $32 million and $10 million in the first, second and third quarter of 2022, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $3,133 million, $3,557 million and $4,002 million in the first, second and third quarter of 2023, respectively, and $2,481 million, $2,709 million and $3,552 million in the
first, second and third quarter of 2022, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
3Q 2023 	3Q 2022 	% Change 	3Q 2023 	3Q 2022 	% Change 	3Q 2023 	3Q 2022 	% Change
TOTAL SALES (1) 	$15,962 	$14,959 	7 	$7,715 	$7,322 	5 	$8,247 	$7,637 	8
PHARMACEUTICAL 	14,263 	12,963 	10 	7,153 	6,620 	8 	7,110 	6,343 	12
Oncology
Keytruda 	6,338 	5,426 	17 	3,795 	3,331 	14 	2,543 	2,095 	21
Alliance Revenue – Lynparza (2) 	299 	284 	5 	153 	144 	7 	146 	140 	4
Alliance Revenue – Lenvima (2) 	260 	202 	29 	160 	142 	13 	100 	60 	67
Welireg 	54 	38 	43 	51 	38 	35 	3 	-
Alliance Revenue – Reblozyl 	52 	39 	35 	43 	32 	34 	10 	7 	42
Vaccines (3)
Gardasil / Gardasil 9 	2,585 	2,294 	13 	838 	957 	-12 	1,746 	1,337 	31
ProQuad / M-M-R II / Varivax 	713 	668 	7 	567 	532 	7 	146 	136 	7
Vaxneuvance 	214 	16 	* 	182 	15 	* 	33 	1 	*
RotaTeq 	156 	256 	-39 	108 	154 	-30 	48 	102 	-53
Pneumovax 23 	140 	131 	6 	42 	68 	-39 	98 	63 	55
Vaqta 	69 	64 	8 	32 	27 	18 	37 	36 	1
Hospital Acute Care
Bridion 	424 	423 	- 	265 	233 	14 	159 	190 	-17
Prevymis 	157 	114 	38 	70 	49 	43 	87 	64 	35
Dificid 	74 	77 	-4 	69 	72 	-3 	5 	6 	-20
Zerbaxa 	53 	43 	23 	29 	24 	19 	24 	19 	27
Noxafil 	51 	62 	-18 	4 	13 	-71 	47 	49 	-3
Primaxin 	41 	63 	-35 	N/M 	41 	63 	-35
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 	92 	88 	5 	96 	85 	13 	-4 	3 	*
Adempas (5) 	65 	57 	15 	65 	57 	15
Virology
Lagevrio 	640 	436 	47 	640 	436 	47
Isentress / Isentress HD 	119 	161 	-27 	58 	68 	-15 	61 	93 	-35
Neuroscience
Belsomra 	58 	62 	-6 	23 	20 	12 	35 	42 	-15
Immunology
Simponi 	179 	173 	3 	179 	173 	3
Remicade 	45 	49 	-8 	45 	49 	-8
Diabetes (6)
Januvia 	581 	717 	-19 	328 	332 	-1 	252 	385 	-34
Janumet 	255 	417 	-39 	43 	90 	-52 	211 	327 	-35
Other Pharmaceutical (7) 	549 	603 	-9 	197 	194 	2 	353 	410 	-14
ANIMAL HEALTH 	1,400 	1,371 	2 	462 	475 	-3 	938 	896 	5
Livestock 	874 	829 	5 	205 	186 	10 	669 	643 	4
Companion Animal 	526 	542 	-3 	257 	289 	-11 	269 	253 	6
Other Revenues (8) 	299 	625 	-52 	100 	227 	-56 	199 	398 	-50
*200% or greater
N/M - Not Meaningful
(6) Total Diabetes sales were $924 million in the third quarter of 2023 and $1,231 million in the third quarter of 2022.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$65 million in the third quarter of 2023 and $10 million in the third quarter of 2022.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $4,002 million in the third quarter of 2023 and $3,552 million in the third quarter of 2022.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
(5) Net product sales in Merck's marketing territories.
6

-- 7 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
Sep YTD
2023
Sep YTD
2022 	% Change
Sep YTD
2023
Sep YTD
2022 	% Change
Sep YTD
2023
Sep YTD
2022 	% Change
TOTAL SALES (1) 	$45,485 	$45,453 	- 	$21,393 	$20,927 	2 	$24,092 	$24,526 	-2
PHARMACEUTICAL 	40,442 	39,826 	2 	19,840 	19,119 	4 	20,602 	20,707 	-1
Oncology
Keytruda 	18,403 	15,487 	19 	11,142 	9,307 	20 	7,261 	6,180 	17
Alliance Revenue – Lynparza (2) 	884 	825 	7 	439 	427 	3 	445 	397 	12
Alliance Revenue – Lenvima (2) 	734 	660 	11 	476 	426 	12 	258 	235 	10
Welireg 	146 	83 	77 	141 	83 	70 	6 	-
Alliance Revenue – Reblozyl (3) 	142 	124 	14 	108 	87 	24 	33 	37 	-10
Vaccines (4)
Gardasil / Gardasil 9 	7,015 	5,428 	29 	1,718 	1,803 	-5 	5,297 	3,624 	46
ProQuad / M-M-R II / Varivax 	1,823 	1,716 	6 	1,435 	1,337 	7 	388 	379 	2
RotaTeq 	584 	644 	-9 	381 	427 	-11 	203 	218 	-7
Vaxneuvance 	488 	32 	* 	423 	31 	* 	65 	1 	*
Pneumovax 23 	327 	457 	-28 	105 	280 	-63 	223 	177 	26
Vaqta 	151 	134 	12 	91 	72 	25 	60 	62 	-3
Hospital Acute Care
Bridion 	1,413 	1,244 	14 	841 	665 	27 	572 	579 	-1
Prevymis 	430 	310 	39 	186 	136 	37 	244 	174 	40
Dificid 	215 	196 	10 	199 	184 	8 	16 	12 	33
Primaxin 	174 	185 	-6 	2 	1 	69 	173 	185 	-6
Noxafil 	167 	180 	-7 	29 	39 	-26 	138 	141 	-2
Zerbaxa 	157 	120 	31 	86 	64 	33 	71 	55 	29
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	259 	258 	- 	249 	244 	2 	10 	14 	-28
Adempas (6) 	189 	181 	5 	189 	181 	5
Virology
Lagevrio 	1,236 	4,859 	-75 	1,523 	-100 	1,236 	3,336 	-63
Isentress / Isentress HD 	377 	466 	-19 	165 	196 	-16 	212 	270 	-21
Neuroscience
Belsomra 	176 	199 	-11 	60 	60 	- 	117 	139 	-16
Immunology
Simponi 	539 	540 	- 	539 	540 	-
Remicade 	144 	163 	-12 	144 	163 	-12
Diabetes (7)
Januvia 	1,642 	2,252 	-27 	842 	958 	-12 	800 	1,294 	-38
Janumet 	937 	1,347 	-30 	182 	258 	-30 	755 	1,089 	-31
Other Pharmaceutical (8) 	1,690 	1,736 	-3 	540 	511 	6 	1,147 	1,225 	-6
ANIMAL HEALTH 	4,347 	4,320 	1 	1,418 	1,425 	-1 	2,929 	2,894 	1
Livestock 	2,530 	2,486 	2 	543 	521 	4 	1,987 	1,965 	1
Companion Animal 	1,817 	1,834 	-1 	875 	904 	-3 	942 	929 	1
Other Revenues (9) 	696 	1,307 	-47 	135 	383 	-65 	561 	925 	-39
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $2,826 million and $3,836 million on a global share basis for September YTD 2023 and 2022, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed
products were $118 million and $156 million on a global share basis for September YTD 2023 and 2022, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $10,692 million and $8,743 million on a global share basis for September YTD 2023 and 2022, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of
sales and commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2023 	2022 	% Change
1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	3Q 	Sep YTD
TOTAL PHARMACEUTICAL 	$12,721 	$13,457 	$14,263 	$40,442 	$14,107 	$12,756 	$12,963 	$39,826 	$12,180 	$52,005 	10 	2
United States 	6,117 	6,570 	7,153 	19,840 	6,773 	5,726 	6,620 	19,119 	5,871 	24,989 	8 	4
% Pharmaceutical Sales 	48.1% 	48.8% 	50.1% 	49.1% 	48.0% 	44.9% 	51.1% 	48.0% 	48.2% 	48.1%
Europe (1) 	2,326 	2,401 	2,497 	7,224 	3,309 	2,677 	2,427 	8,412 	2,494 	10,906 	3 	-14
% Pharmaceutical Sales 	18.3% 	17.8% 	17.5% 	17.9% 	23.5% 	21.0% 	18.7% 	21.1% 	20.5% 	21.0%
China 	1,694 	1,887 	1,674 	5,255 	1,113 	1,355 	1,419 	3,887 	1,216 	5,102 	18 	35
% Pharmaceutical Sales 	13.3% 	14.0% 	11.7% 	13.0% 	7.9% 	10.6% 	10.9% 	9.8% 	10.0% 	9.8%
Japan 	737 	652 	1,062 	2,451 	965 	1,092 	653 	2,710 	832 	3,542 	63 	-10
% Pharmaceutical Sales 	5.8% 	4.8% 	7.4% 	6.1% 	6.8% 	8.6% 	5.0% 	6.8% 	6.8% 	6.8%
Asia Pacific (other than China and Japan) 	703 	705 	636 	2,045 	786 	854 	702 	2,342 	691 	3,034 	-9 	-13
% Pharmaceutical Sales 	5.5% 	5.2% 	4.5% 	5.1% 	5.6% 	6.7% 	5.4% 	5.9% 	5.7% 	5.8%
Latin America 	470 	566 	696 	1,731 	435 	453 	511 	1,399 	472 	1,871 	36 	24
% Pharmaceutical Sales 	3.7% 	4.2% 	4.9% 	4.3% 	3.1% 	3.6% 	3.9% 	3.5% 	3.9% 	3.6%
Eastern Europe/Middle East/Africa 	381 	370 	301 	1,052 	450 	339 	360 	1,149 	320 	1,469 	-16 	-8
% Pharmaceutical Sales 	3.0% 	2.7% 	2.1% 	2.6% 	3.2% 	2.7% 	2.8% 	2.9% 	2.6% 	2.8%
Canada 	141 	127 	133 	401 	189 	166 	166 	521 	158 	678 	-20 	-23
% Pharmaceutical Sales 	1.1% 	0.9% 	0.9% 	1.0% 	1.3% 	1.3% 	1.3% 	1.3% 	1.3% 	1.3%
Other 	152 	179 	111 	443 	87 	94 	105 	287 	126 	414 	6 	54
% Pharmaceutical Sales 	1.2% 	1.6% 	0.9% 	0.9% 	0.6% 	0.6% 	0.9% 	0.7% 	1.0% 	0.8%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
3Q23 	3Q22
Sep YTD
2023
Sep YTD
2022
Interest income 	(73)	$ 	(40)	$ 	(295)	$ 	(62)	$
Interest expense 	317 	244 	836 	727
Exchange losses 	85 	96 	208 	220
Loss (income) from investments in equity securities, net (1) 	33 	371 	(240) 	1,361
Net periodic defined benefit plan (credit) cost other than service cost 	(138) 	(60) 	(364) 	(208)
Other, net 	(98) 	(182) 	243 	(462)
Total 	126	$ 	429	$ 	388	$ 	1,576	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests
in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --